SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-011475
Filing Date
2022-08-01
Accepted
2022-08-01 16:45:37
Documents
14
Period of Report
2022-08-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20220801x8k.htm   iXBRL 8-K 49379
2 EX-10.1 acrs-20220801xex10d1.htm EX-10.1 120121
3 GRAPHIC acrs-20220801xex10d1002.jpg GRAPHIC 797
  Complete submission text file 0001558370-22-011475.txt   319107

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20220801.xsd EX-101.SCH 3058
5 EX-101.LAB acrs-20220801_lab.xml EX-101.LAB 16016
6 EX-101.PRE acrs-20220801_pre.xml EX-101.PRE 10323
8 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20220801x8k_htm.xml XML 4794
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 221125430
SIC: 2834 Pharmaceutical Preparations